Aspect Biosystems is a biotech company based in Vancouver, CN that’s working towards the creation of on-demand human tissues using 3D bioprinting technology. Drug development, tools for therapeutic discovery, and transplantation are just a few of the use cases of the tissues being engineered.
Tamer Mohamed, CEO of Aspect Biosystems, provides a compelling discussion that touches on a variety of topics, including the development of a muscle portfolio composed of intestinal, cardiac, and smooth muscle tissue, a program focused on the development of a liver drug testing platform, and a pancreatic tissue program for the treatment of type 1 diabetes. He also discusses innovative strategies to vascularize tissues, which has been a major challenge in the field of tissue engineering and 3D bioprinting, as well as Aspect Biosystems’ microfluid technology that allows for the creation of multicellular, multi-material tissues.
The team at Aspect Biosystems works closely with academic partners around the world in the development of other applications of engineered tissues, referring to their platform as an “innovation pipeline.” For example, they have partnered with UCLA in the development of new vascular technologies. Interested in learning more? Tune in and visit aspectbiosystems.com.